Xifaxan

Phase 3Small molecule

MMayo Clinic

Xifaxan is one of 64 small molecule programs targeting Abdominal pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Abdominal PainActive, not recruiting

GrowthActive, not recruiting

Abdominal PainPreclinical

Active, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Xifaxan

MMayo Clinic

Phase 3

1 2

Aricept

Eisai

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Zyloprim

Alnylam Pharmaceuticals

Preclinical

1 5

Somavaratan

Glucophage

2 7

Prilosec

DDexcel Pharma Technologies Ltd.

Preclinical

1 8

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Preclinical

1 9

Accutane

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Glucagon

XXeris Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diarrhea1 trial

Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea

Completed·AActavis Inc.·Phase 3·NCT02498418·739 enrolled

Liver Resection1 trial

Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection

Terminated·RRWTH Aachen University·Phase 2·NCT02555293·96 enrolled

Growth1 trial

Transit Time and Bacterial Overgrowth Using SmartPill Capsule

Terminated·MMayo Clinic·N/A·NCT00577772·17 enrolled

Abdominal pain1 trial

Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?

Completed·—·N/A·NCT00619970·115 enrolled

Pilot Study1 trial

A Pilot Study of Xifaxan to Treat Patients With PSC

Completed·MMayo Clinic·Phase 1·NCT01695174·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Xifaxan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xifaxan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xifaxan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMayo Clinic

Xifaxan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diarrhea1 trial

Liver Resection1 trial

Growth1 trial

Abdominal pain1 trial

Pilot Study1 trial

References

Drug Info

Quick Facts

Related News